Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein Following Sorafenib: Outcomes by Liver Disease Aetiology from Two Randomised, Placebo-Controlled Phase 3 Studies (REACH-2 And REACH)

Conference Reports for NATAP

The International Liver Congress™
EASL - European Association for the
Study of the Liver
2019 April 10-14
Vienna Austria


Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein Following Sorafenib: Outcomes by Liver Disease Aetiology from Two Randomised, Placebo-Controlled Phase 3 Studies (REACH-2 And REACH)

	Reported by Jules Levin EASL 2019 April 10-14 Vienna